Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Test de l'ajout du BMS-986016 (Relatlimab) à l'immunothérapie habituelle après le traitement initial du cancer du nasopharynx récurrent ou métastatique

17 novembre 2026 mis à jour par: National Cancer Institute (NCI)

Une étude randomisée de phase II sur le nivolumab par rapport au nivolumab et au BMS-986016 (Relatlimab) comme traitement d'entretien après un traitement de première intention par platine-gemcitabine-nivolumab pour les patients atteints d'un carcinome nasopharyngé récurrent/métastatique associé au virus Epstein-Barr (REMAIN)

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVE:

I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance therapy shows a signal of improved progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients who do not progress following treatment with platinum-gemcitabine-nivolumab combination in the first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC).

SECONDARY OBJECTIVES:

I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves overall survival (OS) compared to nivolumab maintenance alone.

II. To compare patterns of failure (local-regional relapse and distant metastasis) between treatment arms.

III. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves objective response, duration of response, and disease control rate compared to nivolumab maintenance alone.

IV. To evaluate the tolerability of nivolumab-BMS-986016 (relatlimab) maintenance and assess and compare toxicity between arms based on the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) criteria.

V. To evaluate baseline plasma Epstein-Barr virus (EBV) DNA (< 2000 copies/mL versus [vs.] >= 2000 copies/mL) as a prognostic biomarker.

VI. To validate post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a prognostic biomarker.

EXPLORATORY OBJECTIVES:

I. To collect blood and tissue specimens for future translational science studies.

II. To assess post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a predictive biomarker.

OUTLINE:

INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and blood sample collection during screening and on study.

MAINTENANCE THERAPY: Patients who do not progress radiologically are randomized to 1 of 2 arms.

ARM I: Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo positron emission tomography (PET)/CT or bone scan as clinically indicated.

ARM II: Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.

After completion of study treatment, patients are followed up every 4 months for 2 years, every 6 months in years 3-5, and then annually.

Type d'étude

Interventionnel

Inscription (Estimé)

156

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Victoria
      • Melbourne, Victoria, Australie, 3000
        • Recrutement
        • Peter MacCallum Cancer Centre
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 61 3 9656 1521
        • Chercheur principal:
          • Danny Rischin
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • University Health Network-Princess Margaret Hospital
        • Contact:
        • Chercheur principal:
          • Enrique Sanz Garcia
      • Shatin, Hong Kong
        • Recrutement
        • Chinese University of Hong Kong-Prince of Wales Hospital
        • Contact:
        • Chercheur principal:
          • Brigette B. Ma
      • Singapore, Singapour, 119074
        • Recrutement
        • National University Hospital Singapore
        • Contact:
        • Chercheur principal:
          • Boon C. Goh
      • Singapore, Singapour, 168583
        • Recrutement
        • National Cancer Centre Singapore
        • Contact:
        • Chercheur principal:
          • Wan Teck D. Lim
    • California
      • Dublin, California, États-Unis, 94568
        • Recrutement
        • Kaiser Permanente Dublin
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
        • Chercheur principal:
          • Jed A. Katzel
      • Fremont, California, États-Unis, 94538
        • Recrutement
        • Kaiser Permanente-Fremont
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Fresno, California, États-Unis, 93720
        • Recrutement
        • Kaiser Permanente-Fresno
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Fresno, California, États-Unis, 93720
        • Recrutement
        • Kaiser Permanente Fresno Orchard Plaza
        • Chercheur principal:
          • Jed A. Katzel
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 833-574-2273
      • Los Angeles, California, États-Unis, 90033
        • Recrutement
        • USC / Norris Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 323-865-0451
        • Chercheur principal:
          • Jacob S. Thomas
      • Los Angeles, California, États-Unis, 90020
        • Recrutement
        • Keck Medicine of USC Koreatown
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 213-388-0908
        • Chercheur principal:
          • Jacob S. Thomas
      • Los Angeles, California, États-Unis, 90033
        • Recrutement
        • Los Angeles General Medical Center
        • Chercheur principal:
          • Jacob S. Thomas
        • Contact:
      • Modesto, California, États-Unis, 95356
        • Recrutement
        • Kaiser Permanente-Modesto
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Modesto, California, États-Unis, 95356
        • Recrutement
        • Kaiser Permanente- Modesto MOB II
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
        • Chercheur principal:
          • Jed A. Katzel
      • Newport Beach, California, États-Unis, 92663
        • Recrutement
        • USC Norris Oncology/Hematology-Newport Beach
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 323-865-0451
        • Chercheur principal:
          • Jacob S. Thomas
      • Oakland, California, États-Unis, 94611
        • Recrutement
        • Kaiser Permanente-Oakland
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Palo Alto, California, États-Unis, 94304
        • Recrutement
        • Stanford Cancer Institute Palo Alto
        • Chercheur principal:
          • Alexander D. Colevas
        • Contact:
      • Roseville, California, États-Unis, 95661
        • Recrutement
        • Kaiser Permanente-Roseville
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Sacramento, California, États-Unis, 95817
        • Recrutement
        • University of California Davis Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 916-734-3089
        • Chercheur principal:
          • Siao-Yi Wang
      • Sacramento, California, États-Unis, 95814
        • Recrutement
        • Kaiser Permanente Downtown Commons
        • Chercheur principal:
          • Jed A. Katzel
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: kpoct@kp.org
      • Sacramento, California, États-Unis, 95823
        • Recrutement
        • Kaiser Permanente-South Sacramento
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • San Francisco, California, États-Unis, 94115
        • Recrutement
        • Kaiser Permanente-San Francisco
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • San Jose, California, États-Unis, 95119
        • Recrutement
        • Kaiser Permanente-Santa Teresa-San Jose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • San Leandro, California, États-Unis, 94577
        • Recrutement
        • Kaiser Permanente San Leandro
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • San Rafael, California, États-Unis, 94903
        • Recrutement
        • Kaiser San Rafael-Gallinas
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Santa Clara, California, États-Unis, 95051
        • Recrutement
        • Kaiser Permanente Medical Center - Santa Clara
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Santa Rosa, California, États-Unis, 95403
        • Recrutement
        • Kaiser Permanente-Santa Rosa
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • South San Francisco, California, États-Unis, 94080
        • Recrutement
        • Kaiser Permanente-South San Francisco
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Vallejo, California, États-Unis, 94589
        • Recrutement
        • Kaiser Permanente-Vallejo
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
      • Walnut Creek, California, États-Unis, 94596
        • Recrutement
        • Kaiser Permanente-Walnut Creek
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-642-4691
          • E-mail: Kpoct@kp.org
        • Chercheur principal:
          • Jed A. Katzel
    • Georgia
      • Atlanta, Georgia, États-Unis, 30308
        • Recrutement
        • Emory University Hospital Midtown
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 888-946-7447
        • Chercheur principal:
          • Conor E. Steuer
    • Hawaii
      • Honolulu, Hawaii, États-Unis, 96819
        • Recrutement
        • Kaiser Permanente Moanalua Medical Center
        • Contact:
        • Chercheur principal:
          • Jed A. Katzel
    • Idaho
      • Boise, Idaho, États-Unis, 83706
        • Suspendu
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, États-Unis, 83605
        • Suspendu
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, États-Unis, 83814
        • Recrutement
        • Kootenai Health - Coeur d'Alene
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Nampa, Idaho, États-Unis, 83687
        • Suspendu
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, États-Unis, 83854
        • Recrutement
        • Kootenai Clinic Cancer Services - Post Falls
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Sandpoint, Idaho, États-Unis, 83864
        • Recrutement
        • Kootenai Clinic Cancer Services - Sandpoint
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
    • Illinois
      • Chicago, Illinois, États-Unis, 60612
        • Actif, ne recrute pas
        • University of Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Northwestern University
        • Contact:
        • Chercheur principal:
          • Jochen H. Lorch
      • Danville, Illinois, États-Unis, 61832
        • Recrutement
        • Carle at The Riverfront
        • Chercheur principal:
          • Prem Sobti
        • Contact:
      • DeKalb, Illinois, États-Unis, 60115
        • Recrutement
        • Northwestern Medicine Cancer Center Kishwaukee
        • Contact:
        • Chercheur principal:
          • Jochen H. Lorch
      • Effingham, Illinois, États-Unis, 62401
        • Recrutement
        • Carle Physician Group-Effingham
        • Contact:
        • Chercheur principal:
          • Prem Sobti
      • Geneva, Illinois, États-Unis, 60134
        • Recrutement
        • Northwestern Medicine Cancer Center Delnor
        • Contact:
        • Chercheur principal:
          • Jochen H. Lorch
      • Glenview, Illinois, États-Unis, 60026
        • Recrutement
        • Northwestern Medicine Glenview Outpatient Center
        • Chercheur principal:
          • Jochen H. Lorch
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 312-695-1102
      • Grayslake, Illinois, États-Unis, 60030
        • Recrutement
        • Northwestern Medicine Grayslake Outpatient Center
        • Chercheur principal:
          • Jochen H. Lorch
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 312-695-1102
      • Lake Forest, Illinois, États-Unis, 60045
        • Recrutement
        • Northwestern Medicine Lake Forest Hospital
        • Contact:
        • Chercheur principal:
          • Jochen H. Lorch
      • Mattoon, Illinois, États-Unis, 61938
        • Recrutement
        • Carle Physician Group-Mattoon/Charleston
        • Contact:
        • Chercheur principal:
          • Prem Sobti
      • Orland Park, Illinois, États-Unis, 60462
      • Urbana, Illinois, États-Unis, 61801
        • Recrutement
        • Carle Cancer Center
        • Contact:
        • Chercheur principal:
          • Prem Sobti
      • Warrenville, Illinois, États-Unis, 60555
        • Recrutement
        • Northwestern Medicine Cancer Center Warrenville
        • Contact:
        • Chercheur principal:
          • Jochen H. Lorch
    • Iowa
      • Ankeny, Iowa, États-Unis, 50023
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Carroll, Iowa, États-Unis, 51401
        • Recrutement
        • Saint Anthony Regional Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-689-7658
          • E-mail: sbenson@iora.org
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Clive, Iowa, États-Unis, 50325
        • Recrutement
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Council Bluffs, Iowa, États-Unis, 51503
        • Suspendu
        • Heartland Oncology and Hematology LLP
      • Council Bluffs, Iowa, États-Unis, 51503
        • Suspendu
        • Methodist Jennie Edmundson Hospital
      • Council Bluffs, Iowa, États-Unis, 51503
        • Suspendu
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • Broadlawns Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-282-2200
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • Mercy Medical Center - Des Moines
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Richard L. Deming
      • Des Moines, Iowa, États-Unis, 50309
        • Recrutement
        • Iowa Methodist Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-6727
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50309
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, États-Unis, 50501
        • Recrutement
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Chercheur principal:
          • Seema Harichand-Herdt
        • Contact:
      • Waukee, Iowa, États-Unis, 50263
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
    • Missouri
      • St Louis, Missouri, États-Unis, 63128
        • Recrutement
        • Mercy Hospital South
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
      • St Louis, Missouri, États-Unis, 63141
        • Recrutement
        • Mercy Hospital Saint Louis
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 314-251-7066
    • Montana
      • Anaconda, Montana, États-Unis, 59711
        • Recrutement
        • Community Hospital of Anaconda
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, États-Unis, 59101
        • Recrutement
        • Billings Clinic Cancer Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Bozeman, Montana, États-Unis, 59715
        • Recrutement
        • Bozeman Health Deaconess Hospital
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Great Falls, Montana, États-Unis, 59405
        • Recrutement
        • Benefis Sletten Cancer Institute
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Kalispell, Montana, États-Unis, 59901
        • Recrutement
        • Logan Health Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Missoula, Montana, États-Unis, 59804
        • Recrutement
        • Community Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68114
        • Recrutement
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-334-4773
        • Chercheur principal:
          • Yungpo B. Su
      • Omaha, Nebraska, États-Unis, 68114
        • Recrutement
        • Nebraska Methodist Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-354-5144
        • Chercheur principal:
          • Yungpo B. Su
      • Omaha, Nebraska, États-Unis, 68114
        • Suspendu
        • Oncology Associates PC
    • New Jersey
      • Basking Ridge, New Jersey, États-Unis, 07920
        • Recrutement
        • Memorial Sloan Kettering Basking Ridge
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • Middletown, New Jersey, États-Unis, 07748
        • Recrutement
        • Memorial Sloan Kettering Monmouth
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • Montvale, New Jersey, États-Unis, 07645
        • Recrutement
        • Memorial Sloan Kettering Bergen
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • New Brunswick, New Jersey, États-Unis, 08903
        • Recrutement
        • Rutgers Cancer Institute of New Jersey
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 732-235-7356
        • Chercheur principal:
          • Anupama Nehra
    • New York
      • Commack, New York, États-Unis, 11725
        • Recrutement
        • Memorial Sloan Kettering Commack
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • Harrison, New York, États-Unis, 10604
        • Recrutement
        • Memorial Sloan Kettering Westchester
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
      • Uniondale, New York, États-Unis, 11553
        • Recrutement
        • Memorial Sloan Kettering Nassau
        • Chercheur principal:
          • Alan L. Ho
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-639-7592
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • Actif, ne recrute pas
        • University of Cincinnati Cancer Center-UC Medical Center
      • West Chester, Ohio, États-Unis, 45069
        • Actif, ne recrute pas
        • University of Cincinnati Cancer Center-West Chester
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Chercheur principal:
          • Minh Phan
      • Tulsa, Oklahoma, États-Unis, 74146
        • Suspendu
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Ontario, Oregon, États-Unis, 97914
        • Suspendu
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, États-Unis, 97213
        • Recrutement
        • Providence Portland Medical Center
        • Chercheur principal:
          • Dan S. Zuckerman
        • Contact:
      • Portland, Oregon, États-Unis, 97225
        • Recrutement
        • Providence Saint Vincent Medical Center
        • Chercheur principal:
          • Dan S. Zuckerman
        • Contact:
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Recrutement
        • Medical University of South Carolina
        • Contact:
        • Chercheur principal:
          • John M. Kaczmar
    • Washington
      • Seattle, Washington, États-Unis, 98122
        • Recrutement
        • Swedish Medical Center-First Hill
        • Chercheur principal:
          • Dan S. Zuckerman
        • Contact:
    • Wisconsin
      • Mukwonago, Wisconsin, États-Unis, 53149
        • Recrutement
        • ProHealth D N Greenwald Center
        • Contact:
        • Chercheur principal:
          • Timothy R. Wassenaar
      • Oconomowoc, Wisconsin, États-Unis, 53066
        • Recrutement
        • ProHealth Oconomowoc Memorial Hospital
        • Chercheur principal:
          • Timothy R. Wassenaar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 262-928-7878
      • Waukesha, Wisconsin, États-Unis, 53188
        • Recrutement
        • ProHealth Waukesha Memorial Hospital
        • Chercheur principal:
          • Timothy R. Wassenaar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 262-928-7632
      • Waukesha, Wisconsin, États-Unis, 53188
        • Recrutement
        • UW Cancer Center at ProHealth Care
        • Chercheur principal:
          • Timothy R. Wassenaar
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION:

  • Pathologically (histologically or cytologically) proven diagnosis of nasopharyngeal carcinoma (NPC) that has recurred locoregionally and/or is present at distant sites. Patients who present with metastatic disease (de novo) at diagnosis are also eligible. For locoregional recurrence, the disease must not be amenable to potentially curative surgery or re-irradiation. Eligible patient must have the following characteristics:

    • Tumor showing (histological/cytological) Epstein-Barr encoded ribonucleic acid (EBER)-positivity (e.g., In situ hybridization, immunohistochemistry) or
    • A known history of detectable plasma EBV DNA (via a polymerase chain reaction [PCR]-based assay) at any time point since the initial diagnosis of NPC.
  • Measurable disease as defined by RECIST 1.1 criteria. Lesion(s) that have been irradiated previously can be counted as measurable as long as radiological progression after the prior radiation therapy has been demonstrated.

    • Contrast enhanced CT scan of the chest. The contrast enhanced CT component of a whole-body PET-CT is also acceptable. The plain (non-contrast) CT component of a PET-CT is not acceptable.
    • CT the abdomen and pelvis, if clinically indicated (diagnostic quality with contrast, unless contraindicated).
    • Patients with known locoregional disease must have contrast enhanced MRI or CT of the nasopharynx and neck as this disease site(s) may be assessed as target lesions. For patients without known locoregional disease, imaging of the nasopharynx and neck is optional.
    • Symptomatic and active brain metastases and/or leptomeningeal metastasis on CT and/or MRI imaging: Patients who have prior therapies for brain and leptomeningeal metastasis or cord/cauda compression who are clinically stable for >= 2 months prior to registration and have discontinued systemic steroids therapy (> 10 mg/day prednisone or equivalent) > 4 weeks prior to registration are eligible.
    • Patients with base of skull involvement by NPC are allowed unless their disease is directly invading the brain parenchyma, associated with clinical symptoms and/or significant vasogenic edema on radiological imaging.
  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0-2.

  • Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.

  • Absolute neutrophil count (ANC) >= 1500 cells/mm^3.

  • Platelets >= 100,000 cells/mm^3.

  • Hemoglobin (Hgb) >= 8.0 g/dL (Transfusion is accepted. Erythropoietin dependency not accepted.).

  • Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) or direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 × ULN. Patients with known Gilbert's disease who have serum bilirubin level =< 3 × ULN may be enrolled.

  • Alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 × ULN (=< 5 × ULN for patients with liver metastases).

  • Serum creatinine =< 1.5 × ULN or calculated creatinine clearance (CrCl) based on Cockcroft-Gault equation >= 30 mL/min for patients with serum creatinine levels > 1.5 × ULN. Cisplatin or carboplatin may be used at the discretion of the investigator - except for patients with CrCl between 30-50 mL/min, for whom carboplatin should be used instead of cisplatin. CrCl must be > 50 mL/min for cisplatin to be used.

  • Albumin-adjusted calcium level based on corrected calcium equation =< 1.5 × ULN (patients are allowed to have treatment for hypercalcemia prior to starting treatment).

  • No prior systemic treatment of palliative intent for recurrent/metastatic (R/M) NPC including cytotoxic chemotherapy. Prior treatment for non-recurrent and non-metastatic NPC is allowed. Systemic therapy given prior to curative intent re-irradiation or surgery is allowed for potentially curable locoregional recurrence.

  • No prior treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for NPC), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.

  • The interval between the last dose of curative-intent treatment for non-recurrent, non-metastatic NPC, including definitive radiotherapy (RT) and/or induction, concurrent, or adjuvant chemotherapy and recurrence must be ˃ 6 months.

  • Clinically significant toxicities from any prior systemic therapy or radiotherapy must have resolved to grade 0 or 1 as per National Cancer Institute (NCI) CTCAE v 5.0 - except alopecia, dry mouth, dysgeusia, dysphagia, and fatigue. Patients with a history of grade 3-4 cisplatin related neuropathy must have recovered to grade 0-2 prior to registration. Patients with a history of hearing impairment, or ototoxicity from prior cisplatin, of any grade are allowed.

  • No prior palliative RT within 30 days prior to registration unless the irradiated site(s) are not the target lesions. The irradiated site(s) also must not be the only sites of measurable recurrent disease.

  • No major surgical procedures within 30 days prior to registration.

  • No history of unstable angina requiring hospitalization within the last 6 months.

  • No history of myocardial infarction within the last 6 months.

  • New York Heart Association Functional Classification II or better (New York Heart Association [NYHA] Functional Classification III/IV are not eligible). Patients with symptomatic coronary artery disease, congestive heart failure or a known history of having a left ventricular ejection fraction < 50% must be stably controlled with medication in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  • No prior history of myocarditis.

  • No active infection requiring IV antibiotics, IV antiviral, or IV antifungal treatments at the time of study registration.

  • No history of (non-infectious) pneumonitis that required steroids or current pneumonitis requiring steroids and/or immunosuppressive therapy, idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), or idiopathic pneumonitis.

  • No history of multi-drug resistant mycobacterium tuberculosis (TB) or active TB, as defined by systemic treatment received =< 2 years prior to registration. Note: Patients who had a history of treated TB ˃ 2 years prior to registration are allowed.

  • No prior solid organ transplant or bone marrow transplant.

  • No conditions requiring systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid premedication for the prophylaxis of CT contrast-related allergies is allowed. The use of dexamethasone as an anti-emetic premedication prior to chemotherapy is also allowed.

  • No active autoimmune disease requiring systemic treatment (i.e., disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These may include (but not limited to) patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, autoimmune hepatitis, glomerulonephritis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome.

    • Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; alopecia; and/or psoriasis not requiring systemic treatment. Conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • No prior live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live attenuated vaccines and are not allowed. Coronavirus disease 2019 (COVID-19) vaccines that are approved by the local drug regulatory authority of the participating region are allowed.

  • No known history of grade 3-4 allergic reaction or hypersensitivity reaction to cisplatin, carboplatin, or gemcitabine.

  • No known history of grade 4 hypersensitivity (or infusion) reaction to any monoclonal antibody. Patients who had prior grade 3 hypersensitivity (or infusion) reaction but could tolerate resumption of the antibody treatment after appropriate pre-medication are eligible.

  • PRIOR TO STEP 2 REGISTRATION:

  • Collection of plasma EBV DNA at baseline is mandatory for all patients prior to Step 2 registration and induction treatment.

    • Note: Submission of the baseline sample will be batch shipped.
  • PRIOR TO STEP 3 REGISTRATION/RANDOMIZATION: PATIENTS WITHOUT PROGRESSIVE DISEASE (PD) ONLY:

  • All patients must have received minimum of 3 cycles, and up to a maximum of 6 cycles of induction treatment within 20 weeks from cycle 1, day 1 of induction treatment (i.e., patients must have completed all induction treatment within 20 weeks from cycle 1 day 1, including the treatment breaks). Patients must have completed 6 cycles of induction treatment, except in the following circumstances:

    • Significant dose delays as a result of treatment-related toxicities.
    • Intercurrent illness(s), that rendered the patient unable to continue induction treatment.
    • Note: If a patient received < 6 cycles of induction treatment for reasons other than the above circumstances, they will not be eligible for randomization.
  • A CT scan within 30 days prior to Step 3 registration/randomization is required. If the most recent scan performed is not within this time frame, a repeat scan is required to assess response.

  • Did not meet any criteria that result in permanent discontinuation of study treatment during induction treatment phase.

  • Must meet the criteria for starting/resuming a new cycle of maintenance treatment.

  • Did not experience any nivolumab-related autoimmune toxicities that would result in permanent discontinuation of nivolumab during the induction treatment phase.

  • Collection of the plasma EBV DNA post-induction treatment is mandatory.

    • Note: Submission of the post-induction sample will be batch shipped.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm I (Nivolumab)

Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Given IV

Autres noms:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilaire CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • PAS 206
  • Nivolumab Biosimilaire ABP 206
  • BCD-263
  • Nivolumab biosimilaire BCD-263
  • BMS936558
  • ONO4538

Undergo CT or PET/CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Undergo PET/CT

Autres noms:
  • Imagerie médicale, Tomographie par émission de positrons
  • ANIMAUX
  • TEP-scan
  • Scan de tomographie par émission de positrons
  • Tomographie par émission de positrons
  • PT
  • Tomographie par émission de positrons (procédure)

Undergo bone scan

Autres noms:
  • Scintigraphie osseuse
Expérimental: Arm II (Nivolumab, relatlimab)

Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Given IV

Autres noms:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilaire CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • PAS 206
  • Nivolumab Biosimilaire ABP 206
  • BCD-263
  • Nivolumab biosimilaire BCD-263
  • BMS936558
  • ONO4538

Undergo CT or PET/CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Undergo PET/CT

Autres noms:
  • Imagerie médicale, Tomographie par émission de positrons
  • ANIMAUX
  • TEP-scan
  • Scan de tomographie par émission de positrons
  • Tomographie par émission de positrons
  • PT
  • Tomographie par émission de positrons (procédure)

Given IV

Autres noms:
  • BMS-986016
  • BMS986016
  • Immunoglobuline G4, anti-(protéine du gène 3 d'activation des lymphocytes humains) (chaîne lourde humaine), disulfure avec chaîne légère humaine, dimère
  • GTB 986016

Undergo bone scan

Autres noms:
  • Scintigraphie osseuse
Expérimental: Induction therapy (Platinum-gemcitabine-nivolumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection during screening and on study.

Given IV

Autres noms:
  • Blastocarbe
  • Carboplat
  • Carboplatine Hexal
  • Carboplatine
  • Carbosine
  • Carbosol
  • Carbotec
  • CBDCA
  • Afficher
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatine
  • Paraplatine
  • Paraplatine AQ
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Autres noms:
  • CDDP
  • Cis-diamminedichloridoplatine
  • Cismaplat
  • Cisplatine
  • Néoplatine
  • Platinol
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloroplatine
  • Cis-diamminedichloro Platine (II)
  • Cis-diamminedichloroplatine
  • Cis-dichloroammine Platine (II)
  • Dichlorure de diamine cis-platineux
  • Cis-platine
  • Cis-platine II
  • Cis-platine II dichlorure de diamine
  • Cisplatyle
  • Citoplatino
  • Citosine
  • Cysplatyna
  • DDP
  • Lederplatine
  • Métaplatine
  • Chlorure de Peyrone
  • Sel de Peyrone
  • Placis
  • Plastique
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxane
  • Platine
  • Diamminodichlorure de platine
  • Platiran
  • Platistine
  • Platosine

Undergo blood sample collection

Autres noms:
  • Collecte d'échantillons biologiques
  • Spécimen biologique collecté
  • Collecte de spécimens
  • Collection d'échantillons

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Given IV

Autres noms:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilaire CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • PAS 206
  • Nivolumab Biosimilaire ABP 206
  • BCD-263
  • Nivolumab biosimilaire BCD-263
  • BMS936558
  • ONO4538

Undergo CT or PET/CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Given IV

Autres noms:
  • dFdCyd
  • dFdC
  • Difluorodésoxycytidine

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS)
Délai: Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years

Will be assessed in both treatment arms and will be estimated using the Kaplan-Meier method. The comparison of PFS distributions between treatment arms will be performed using the log-rank test. Additional analyses of treatment effect will be performed using Cox models with the stratification factors included as a fixed covariates, as well as other tumor and patient characteristics, listed below. Median PFS and the corresponding 95% confidence intervals (CIs) for each arm will be estimated with the Brookmeyer-Crowley method. Multivariable analysis will be performed using a Cox proportional hazards model and relevant patient and tumor characteristics (country [Asian sites versus (vs.) Non-Asian sites], keratinizing squamous carcinoma, sex, age, and baseline Epstein-Barr virus (EBV) deoxyribonucleic acid [DNA]). Hazard ratios and their respective 85% lower confidence bound, and 95% confidence intervals will be provided.

Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall survival (OS)
Délai: Time from randomization to death due to any cause, assessed up to 6 years

Will be estimated using the Kaplan-Meier method and between-arm differences will be assessed using the log-rank test. Median OS and the corresponding 95% CIs using log-log transformation to survival function for each arm will be estimated with the Brookmeyer-Crowley method.

Time from randomization to death due to any cause, assessed up to 6 years
Tumor response
Délai: Up to 6 years

Will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.

Up to 6 years
Locoregional failure
Délai: Up to 6 years

Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.

Up to 6 years
Distant metastasis
Délai: Up to 6 years

Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.

Up to 6 years
Incidence of adverse events (AEs)
Délai: Up to 6 years

Will be graded using Common Terminology Criteria for Adverse Events version 5.0. Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The rate of patients with at least 1 grade 3 or higher AE will be compared between the treatment arms using a chi-square test for proportions and confidence intervals for rate difference will be computed using Miettinen-Nurminen (score) method

Up to 6 years
Post-induction plasma EBV DNA as a prognostic biomarker
Délai: Up to 6 years

Will be defined as a binary biomarker (detectable: >= 1 copies/mL vs. undetectable: 0 copies/mL). Biomarker effect HRs from multivariable Cox models, including key tumor and patient characteristics will also be reported.

Up to 6 years
Pre-induction plasma EBV DNA vs. progressive disease (PD) during induction treatment
Délai: Up to 6 years

Will include all patients treated with concurrent (induction) treatment and a binary biomarker based on pre-induction plasma EBV DNA (< 2000 vs. ≥2000 copies/mL). PD rates during induction for each biomarker subgroup will be computed assuming a binomial distribution and compared between biomarker subgroups using a chi-square test. Multivariable Cox models, including key tumor and patient characteristics will also be included.

Up to 6 years
Persistent plasma EBV DNA vs. PFS
Délai: Up to 6 years

Will examine the association between persistent EBV DNA after induction treatment and PFS. Only randomized patients with positive pre-induction plasma EBV DNA will be included (~90-95%). Patients will be classified into "EBV DNA positive to negative" and "EBV DNA consistently positive" based on the pre-induction and post-induction EBV DNA. Multivariable Cox models, including key tumor and patient characteristics will also be included.

Up to 6 years

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Post-induction EBV DNA as a predictive biomarker
Délai: Up to 6 years

Will be assessed of the predictive role of post-induction EBV DNA on PFS and OS will be performed using the binary biomarker. Cox proportional hazards model with treatment arm, binary biomarker, and its interaction will be used for these analyses. Treatment effect hazard ratios and 95% confidence intervals will be reported. Adjusted HR estimates will be obtained after adding key patient and tumor characteristics.

Up to 6 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Brigette B Ma, NRG Oncology

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 juillet 2024

Achèvement primaire (Estimé)

30 avril 2029

Achèvement de l'étude (Estimé)

30 avril 2029

Dates d'inscription aux études

Première soumission

7 septembre 2023

Première soumission répondant aux critères de contrôle qualité

7 septembre 2023

Première publication (Réel)

8 septembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NCI-2023-06678
  • U10CA180868 (Subvention/contrat des NIH des États-Unis)
  • NCI-2023-06678 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
  • NRG-HN011 (Autre identifiant: CTEP)
  • NRG-HN011 (Autre identifiant: NRG Oncology)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner